Wenbin Kuang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Wenbin Kuang has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
- Peng Yang
China Pharmaceutical University
6 shared publications - Xiao Wang
State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, China
5 shared publications Liping Wang
State Key Laboratory of Natural Medicines China Pharmaceutical University Nanjing 210009 China
4 shared publicationsHao Shen
State Key Laboratory of Natural Medicines China Pharmaceutical University Nanjing 210009 China
3 shared publicationsJiaxing Li
State Key Laboratory of Natural Medicines China Pharmaceutical University Nanjing 210009 China
3 shared publicationsWenjian Min
State Key Laboratory of Natural Medicines China Pharmaceutical University Nanjing 210009 China
3 shared publications
Latest Publications
- Open Access
- 20 June 2025
- Published by Wiley in Advanced Science
- Vol. 12 (33) , e06718
ASO Therapy Targeting STAU2 to Inhibit Pancreatic Ductal Adenocarcinoma Progression and Metastasis by Regulating the PALLD‐Mediated EMT Signaling Pathway
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy marked by high morbidity, recurrence, and metastasis, with limited treatment options and poor prognosis. The challenge of early diagnosis and the inefficacy of current therapeutic strategies underscore the urgent need for novel biomarkers and therapeutic targets. RNA‐binding proteins (RBPs) are emerging as critical regulators of post‐transcriptional processes and are implicated in cancer progression. Here, the study identifies Staufen Double‐Stranded RNA Binding Protein 2 (STAU2) as an oncogenic RBP with high expression in PDAC, which is significantly associated with metastasis. It is demonstrated that STAU2 directly binds and regulates cytoskeletal associated protein Palladin (PALLD) and mediates IQ motif containing GTPase‐activating protein 1 (IQGAP1), thereby promoting metastasis via the epithelial‐mesenchymal transition (EMT) pathway. Moreover, a 2′‐methoxyethoxy (2′‐MOE)‐modified antisense oligonucleotide (ASO) targeting STAU2 is developed, which effectively inhibited downstream targets in vitro and in vivo. STAU2‐ASO treatment significantly suppressed PDAC progression and metastasis, with a demonstrated safety profile in vivo.
- 20 June 2025
- Published by Wiley in Advanced Science
- Vol. 12 (33) , e06718
Open AccessASO Therapy Targeting STAU2 to Inhibit Pancreatic Ductal Adenocarcinoma Progression and Metastasis by Regulating the PALLD‐Mediated EMT Signaling Pathway
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy marked by high morbidity, recurrence, and metastasis, with limited treatment options and poor prognosis. The challenge of early diagnosis and the inefficacy of current therapeutic strategies underscore the urgent need for novel biomarkers and therapeutic targets. RNA‐binding proteins (RBPs) are emerging as critical regulators of post‐transcriptional processes and are implicated in cancer progression. Here, the study identifies Staufen Double‐Stranded RNA Binding Protein 2 (STAU2) as an oncogenic RBP with high expression in PDAC, which is significantly associated with metastasis. It is demonstrated that STAU2 directly binds and regulates cytoskeletal associated protein Palladin (PALLD) and mediates IQ motif containing GTPase‐activating protein 1 (IQGAP1), thereby promoting metastasis via the epithelial‐mesenchymal transition (EMT) pathway. Moreover, a 2′‐methoxyethoxy (2′‐MOE)‐modified antisense oligonucleotide (ASO) targeting STAU2 is developed, which effectively inhibited downstream targets in vitro and in vivo. STAU2‐ASO treatment significantly suppressed PDAC progression and metastasis, with a demonstrated safety profile in vivo.
- Open Access
- 19 December 2024
- Published by Springer Nature in Leukemia
- Vol. 39 (3) , 599-613
ADAR1 is required for acute myeloid leukemia cell survival by modulating post-transcriptional Wnt signaling through impairing miRNA biogenesis
Recent extensive studies on the genomic and molecular profiles of acute myeloid leukemia (AML) have expanded the treatment options, including, a range of compounds represented by fms-like tyrosine kinase 3 and isocitrate dehydrogenase 1/2 inhibitors. However, despite this progress, further treatments for AML are still required. Adenosine deaminase acting on RNA 1 (ADAR1) has been shown to play an important oncogenic role in many cancers, but its involvement in AML progression remains underexplored. In this study, we demonstrated that ADAR1 was overexpressed in AML and served as a crucial oncogenic target. Loss of ADAR1 inhibited the Wnt signaling pathway, blocked AML cell proliferation, and induced apoptosis. Importantly, we demonstrate that ADAR1, as an RNA-binding protein, interacts with pri-miR-766 independently of its editing function, regulating the maturation of miR-766-3p and enhancing the expression of WNT5B. Genetic inhibition or use of the ADAR1 inhibitor ZYS-1 significantly suppressed AML cell growth both in vitro and in vivo. Overall, these results elucidated the tumorigenic mechanism of ADAR1 and validated it as a potential drug target in AML.
- 19 December 2024
- Published by Springer Nature in Leukemia
- Vol. 39 (3) , 599-613
Open AccessADAR1 is required for acute myeloid leukemia cell survival by modulating post-transcriptional Wnt signaling through impairing miRNA biogenesis
Recent extensive studies on the genomic and molecular profiles of acute myeloid leukemia (AML) have expanded the treatment options, including, a range of compounds represented by fms-like tyrosine kinase 3 and isocitrate dehydrogenase 1/2 inhibitors. However, despite this progress, further treatments for AML are still required. Adenosine deaminase acting on RNA 1 (ADAR1) has been shown to play an important oncogenic role in many cancers, but its involvement in AML progression remains underexplored. In this study, we demonstrated that ADAR1 was overexpressed in AML and served as a crucial oncogenic target. Loss of ADAR1 inhibited the Wnt signaling pathway, blocked AML cell proliferation, and induced apoptosis. Importantly, we demonstrate that ADAR1, as an RNA-binding protein, interacts with pri-miR-766 independently of its editing function, regulating the maturation of miR-766-3p and enhancing the expression of WNT5B. Genetic inhibition or use of the ADAR1 inhibitor ZYS-1 significantly suppressed AML cell growth both in vitro and in vivo. Overall, these results elucidated the tumorigenic mechanism of ADAR1 and validated it as a potential drug target in AML.
- 12 August 2024
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 277, 116774
Regulation of protein phosphorylation by PTPN2 and its small-molecule inhibitors/degraders as a potential disease treatment strategy
- 12 August 2024
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 277, 116774
Regulation of protein phosphorylation by PTPN2 and its small-molecule inhibitors/degraders as a potential disease treatment strategy
- Open Access
- 1 July 2023
- Published by KEAI Publishing in Genes & Diseases
- Vol. 10 (4) , 1206-1209
Pan-cancer analysis of DNA methyltransferase family with potential implications in prognosis and immunology in human cancer
- 1 July 2023
- Published by KEAI Publishing in Genes & Diseases
- Vol. 10 (4) , 1206-1209
Open AccessPan-cancer analysis of DNA methyltransferase family with potential implications in prognosis and immunology in human cancer
- Open Access
Systematic Identification of the RNA-Binding Protein STAU2 as a Key Regulator of Pancreatic Adenocarcinoma
Pancreatic adenocarcinoma (PAAD) is a highly aggressive cancer. RNA-binding proteins (RBPs) regulate highly dynamic post-transcriptional processes and perform very important biological functions. Although over 1900 RBPs have been identified, most are considered markers of tumor progression, and further information on their general role in PAAD is not known. Here, we report a bioinformatics analysis that identified five hub RBPs and produced a high-value prognostic model based on The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) datasets. Among these, the prognostic signature of the double-stranded RNA binding protein Staufen double-stranded RNA (STAU2) was identified. Firstly, we found that it is a highly expressed critical regulator of PAAD associated with poor clinical outcomes. Accordingly, the knockdown of STAU2 led to a profound decrease in PAAD cell growth, migration, and invasion and induced apoptosis of PAAD cells. Furthermore, through multiple omics analyses, we identified the key target genes of STAU2: Palladin cytoskeletal associated protein (PALLD), Heterogeneous nuclear ribonucleoprotein U (HNRNPU), SERPINE1 mRNA Binding Protein 1 (SERBP1), and DEAD-box polypeptide 3, X-Linked (DDX3X). Finally, we found that a high expression level of STAU2 not only helps PAAD evade the immune response but is also related to chemotherapy drug sensitivity, which implies that STAU2 could serve as a potential target for combinatorial therapy. These findings uncovered a novel role for STAU2 in PAAD aggression and resistance, suggesting that it probably represents a novel therapeutic and drug development target.
Open AccessSystematic Identification of the RNA-Binding Protein STAU2 as a Key Regulator of Pancreatic Adenocarcinoma
Pancreatic adenocarcinoma (PAAD) is a highly aggressive cancer. RNA-binding proteins (RBPs) regulate highly dynamic post-transcriptional processes and perform very important biological functions. Although over 1900 RBPs have been identified, most are considered markers of tumor progression, and further information on their general role in PAAD is not known. Here, we report a bioinformatics analysis that identified five hub RBPs and produced a high-value prognostic model based on The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) datasets. Among these, the prognostic signature of the double-stranded RNA binding protein Staufen double-stranded RNA (STAU2) was identified. Firstly, we found that it is a highly expressed critical regulator of PAAD associated with poor clinical outcomes. Accordingly, the knockdown of STAU2 led to a profound decrease in PAAD cell growth, migration, and invasion and induced apoptosis of PAAD cells. Furthermore, through multiple omics analyses, we identified the key target genes of STAU2: Palladin cytoskeletal associated protein (PALLD), Heterogeneous nuclear ribonucleoprotein U (HNRNPU), SERPINE1 mRNA Binding Protein 1 (SERBP1), and DEAD-box polypeptide 3, X-Linked (DDX3X). Finally, we found that a high expression level of STAU2 not only helps PAAD evade the immune response but is also related to chemotherapy drug sensitivity, which implies that STAU2 could serve as a potential target for combinatorial therapy. These findings uncovered a novel role for STAU2 in PAAD aggression and resistance, suggesting that it probably represents a novel therapeutic and drug development target.
- Open Access
- 1 October 2020
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. ume 13, 10149-10159
The Novel Circular RNA Circ-PGAP3 Promotes the Proliferation and Invasion of Triple Negative Breast Cancer by Regulating the miR-330-3p/Myc Axis
Background: Triple negative breast cancer (TNBC), a special subtype of breast cancer, is characterized by high recurrence, mortality and few treatments. To date, the key factors contributing to TNBC progression have not been fully identified. In the current study, we found a TNBC-related circular RNA (circRNA), circ-PGAP3, and explored its biological function, clinical significance and potential mechanism of action. Materials and Methods: The functional assay was carried out using CCK-8, colony formation and Transwell invasion assays. RIP, RNA pull-down and luciferase reporter assays were used to test the correlation between circ-PGAP3, miR-330-3p and Myc. The animal model was employed to verify the function of circ-PGAP3 in vivo. Results: Circ-PGAP3 expression was significantly increased in TNBC tissues. High circ-PGAP3 was closely associated with large tumor size, lymph node metastasis, later TNM stage and dismal outcome. Through performing a series of in vitro and in vivo experiments, we found that circ-PGAP3 promoted TNBC cell growth and metastasis via sponging and inhibiting miR-330-3p, resulting in the upregulation of proto-oncogene Myc. Importantly, circ-PGAP3 expression was positively correlated with the Myc protein level but negatively correlated with miR-330-3p expression in TNBC tissues. Moreover, silencing of miR-330-3p or overexpression of Myc could effectively rescue the weakened malignant phenotype induced by circ-PGAP3 knockdown. Conclusion: Our results unveil the important driving role of circ-PGAP3 in TNBC development and progression, which provides a candidate therapeutic target for TNBC patients.
- 1 October 2020
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. ume 13, 10149-10159
Open AccessThe Novel Circular RNA Circ-PGAP3 Promotes the Proliferation and Invasion of Triple Negative Breast Cancer by Regulating the miR-330-3p/Myc Axis
Background: Triple negative breast cancer (TNBC), a special subtype of breast cancer, is characterized by high recurrence, mortality and few treatments. To date, the key factors contributing to TNBC progression have not been fully identified. In the current study, we found a TNBC-related circular RNA (circRNA), circ-PGAP3, and explored its biological function, clinical significance and potential mechanism of action. Materials and Methods: The functional assay was carried out using CCK-8, colony formation and Transwell invasion assays. RIP, RNA pull-down and luciferase reporter assays were used to test the correlation between circ-PGAP3, miR-330-3p and Myc. The animal model was employed to verify the function of circ-PGAP3 in vivo. Results: Circ-PGAP3 expression was significantly increased in TNBC tissues. High circ-PGAP3 was closely associated with large tumor size, lymph node metastasis, later TNM stage and dismal outcome. Through performing a series of in vitro and in vivo experiments, we found that circ-PGAP3 promoted TNBC cell growth and metastasis via sponging and inhibiting miR-330-3p, resulting in the upregulation of proto-oncogene Myc. Importantly, circ-PGAP3 expression was positively correlated with the Myc protein level but negatively correlated with miR-330-3p expression in TNBC tissues. Moreover, silencing of miR-330-3p or overexpression of Myc could effectively rescue the weakened malignant phenotype induced by circ-PGAP3 knockdown. Conclusion: Our results unveil the important driving role of circ-PGAP3 in TNBC development and progression, which provides a candidate therapeutic target for TNBC patients.
- 8 June 2020
- Published by Springer Nature in Human Cell
- Vol. 33 (4) , 1204-1217
Development of a novel insulin receptor (IR) antagonist that exhibits anti-breast tumor activity
Many reports have indicated that the insulin receptor (IR) causes tumorigenesis and the development of breast cancer. It has been considered a potential target for treating IR-related tumors. Traditionally, there are two categories of insulin receptor (IR) antagonists, they are small molecule antagonists and anti-IR antibodies. Here, we describe a new method (anti-idiotypic antibody strategy) for the development of IR antagonist. Hybridoma technology was employed to design and identify a series of anti-idiotypic antibodies against insulin. After repeated screening and identification, an anti-idiotypic antibody against IR (AK98) was obtained. Analysis through competitive ELISA and competitive receptor binding indicated that AK98 mimicked the receptor binding epitope of insulin. The interaction between AK98 and IR was determined using indirect immunofluorescence, immunoelectron microscopy, and Immunoprecipitation-Western (IP-WB). Further research using a tumor cell model revealed that AK98 inhibited insulin-IR binding and IR-mediated intracellular signaling pathways. Conclusively, the main purpose of this paper is that we proposed a new method (anti-idiotypic antibody strategy) to develop the insulin receptor (IR) antagonist (AK98), and a series of experiments showed that the anti-idiotypic antibody (AK98) exhibited good antagonistic activity against IR. This work suggests that the anti-idiotypic antibody may be a potential strategy to develop IR antagonists that can be used in treating breast cancer.
- 8 June 2020
- Published by Springer Nature in Human Cell
- Vol. 33 (4) , 1204-1217
Development of a novel insulin receptor (IR) antagonist that exhibits anti-breast tumor activity
Many reports have indicated that the insulin receptor (IR) causes tumorigenesis and the development of breast cancer. It has been considered a potential target for treating IR-related tumors. Traditionally, there are two categories of insulin receptor (IR) antagonists, they are small molecule antagonists and anti-IR antibodies. Here, we describe a new method (anti-idiotypic antibody strategy) for the development of IR antagonist. Hybridoma technology was employed to design and identify a series of anti-idiotypic antibodies against insulin. After repeated screening and identification, an anti-idiotypic antibody against IR (AK98) was obtained. Analysis through competitive ELISA and competitive receptor binding indicated that AK98 mimicked the receptor binding epitope of insulin. The interaction between AK98 and IR was determined using indirect immunofluorescence, immunoelectron microscopy, and Immunoprecipitation-Western (IP-WB). Further research using a tumor cell model revealed that AK98 inhibited insulin-IR binding and IR-mediated intracellular signaling pathways. Conclusively, the main purpose of this paper is that we proposed a new method (anti-idiotypic antibody strategy) to develop the insulin receptor (IR) antagonist (AK98), and a series of experiments showed that the anti-idiotypic antibody (AK98) exhibited good antagonistic activity against IR. This work suggests that the anti-idiotypic antibody may be a potential strategy to develop IR antagonists that can be used in treating breast cancer.